TARDBP and amyotrophic lateral sclerosis: ALS patient-derived iPSCs included three commercially available cell lines as follows: UCLi004-A containing GGGGCC repeat expansion, PFIZi013-A containing TARDBP A382T mutation, and WC034i containing SOD1 D90A mutation (WiCell Research).